Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Aptose Biosciences Inc is a biotechnology business based in the US. Aptose Biosciences shares (APTO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptose Biosciences employs 39 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$2.14|
|52-week range||$2.11 - $7.27|
|50-day moving average||$2.46|
|200-day moving average||$3.59|
|Wall St. target price||$10.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.65|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||N/A|
|1 month (2021-09-22)||N/A|
|3 months (2021-07-26)||-21.32%|
|6 months (2021-04-26)||-59.47%|
|1 year (2020-10-26)||-54.95%|
|2 years (2019-10-25)||3.38%|
|3 years (2018-10-26)||4.90%|
|5 years (2016-10-26)||38.96%|
|Gross profit TTM||$0|
|Return on assets TTM||-37.72%|
|Return on equity TTM||-65%|
|Market capitalisation||$194.8 million|
TTM: trailing 12 months
There are currently 785,611 Aptose Biosciences shares held short by investors – that's known as Aptose Biosciences's "short interest". This figure is 16.7% down from 942,567 last month.
There are a few different ways that this level of interest in shorting Aptose Biosciences shares can be evaluated.
Aptose Biosciences's "short interest ratio" (SIR) is the quantity of Aptose Biosciences shares currently shorted divided by the average quantity of Aptose Biosciences shares traded daily (recently around 818344.79166667). Aptose Biosciences's SIR currently stands at 0.96. In other words for every 100,000 Aptose Biosciences shares traded daily on the market, roughly 960 shares are currently held short.
However Aptose Biosciences's short interest can also be evaluated against the total number of Aptose Biosciences shares, or, against the total number of tradable Aptose Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptose Biosciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Aptose Biosciences shares in existence, roughly 10 shares are currently held short) or 0.0089% of the tradable shares (for every 100,000 tradable Aptose Biosciences shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aptose Biosciences.
Find out more about how you can short Aptose Biosciences stock.
We're not expecting Aptose Biosciences to pay a dividend over the next 12 months.
Aptose Biosciences's shares were split on a 1:12 basis on 5 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptose Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aptose Biosciences shares which in turn could have impacted Aptose Biosciences's share price.
Over the last 12 months, Aptose Biosciences's shares have ranged in value from as little as $2.11 up to $7.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptose Biosciences's is 1.3285. This would suggest that Aptose Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aptose Biosciences Inc. , a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.